Your browser doesn't support javascript.
The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.
Kocatürk, Emek; Salman, Andaç; Cherrez-Ojeda, Ivan; Criado, Paulo Ricardo; Peter, Jonny; Comert-Ozer, Elif; Abuzakouk, Mohamed; Agondi, Rosana Câmara; Al-Ahmad, Mona; Altrichter, Sabine; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Bauer, Andrea; Ben-Shoshan, Moshe; Bernstein, Jonathan A; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bonnekoh, Hanna; Bouillet, Laurence; Brzoza, Zenon; Busse, Paula; Campos, Regis A; Carne, Emily; Conlon, Niall; Criado, Roberta F; de Souza Lima, Eduardo M; Demir, Semra; Dissemond, Joachim; Dogan Günaydin, Sibel; Dorofeeva, Irina; Ensina, Luis Felipe; Ertas, Ragip; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fomina, Daria; Franken, Sylvie M; Fukunaga, Atsushi; Giménez-Arnau, Ana M; Godse, Kiran; Gonçalo, Margarida; Gotua, Maia; Grattan, Clive; Guillet, Carole; Inomata, Naoko; Jakob, Thilo; Karakaya, Gul; Kasperska-Zajac, Alicja; Katelaris, Constance H; Kosnik, Mitja.
  • Kocatürk E; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
  • Salman A; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.
  • Cherrez-Ojeda I; Urticaria Center of Reference and Excellence (UCARE), School of Medicine, Universidad de Especialidades Espíritu Santo, Samborondón, Ecuador and RespiraLab, Research, Guayaquil, Ecuador.
  • Criado PR; Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC, Santo André, Brazil.
  • Peter J; Alergoskin Alergia e Dermatologia SS ltda, Santo André, Brazil.
  • Comert-Ozer E; UCARE Center, São Paulo, Brazil.
  • Abuzakouk M; Urticaria Center of Reference and Excellence (UCARE), Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, 7925, South Africa.
  • Agondi RC; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.
  • Al-Ahmad M; Urticaria Center of Reference and Excellence (UCARE), Cleveland Clinic Abu Dhabi, UAE.
  • Altrichter S; Urticaria Center of Reference and Excellence (UCARE), University of São Paulo, São Paulo, Brazil.
  • Arnaout R; Urticaria Center of Reference and Excellence (UCARE), Microbiology Department, Faculty of Medicine, Kuwait University, Safat, Kuwait.
  • Arruda LK; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Asero R; Urticaria Center of Reference and Excellence (UCARE), King Faisal Specialist Hospital & Research Center, Al Faisal University, Riyadh, Saudi Arabia.
  • Bauer A; Urticaria Center of Reference and Excellence (UCARE), Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Ben-Shoshan M; Urticaria Center of Reference and Excellence (UCARE), Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
  • Bernstein JA; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
  • Bizjak M; Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University Health Center, Montreal, QC, Canada.
  • Boccon-Gibod I; Urticaria Center of Reference and Excellence (UCARE), University of Cincinnati College of Medicine, Division of Immunology, Rheumatology and Allergy, Cincinnati, USA.
  • Bonnekoh H; Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
  • Bouillet L; Urticaria Center of Reference and Excellence (UCARE), Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble, France.
  • Brzoza Z; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Busse P; Autoinflammation Reference Center Charité (ARC2), Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Campos RA; Urticaria Center of Reference and Excellence (UCARE), Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble, France.
  • Carne E; Urticaria Center of Reference and Excellence (UCARE), Department of Internal Medicine with Division of Allergology, Institute of Medical Sciences, University of Opole, Opole, Poland.
  • Conlon N; Urticaria Center of Reference and Excellence (UCARE), Division of Clinical Immunology and Allergy, Icahn School at Mount Sinai, New York, NY, USA.
  • Criado RF; Urticaria Center of Reference and Excellence (UCARE), Universidade Federal da Bahia, Salvador, Brazil.
  • de Souza Lima EM; Serviço de Imunologia, Hospital das Clínicas Professor Edgard Santos, Salvador, Brazil.
  • Demir S; Urticaria Center of Reference and Excellence (UCARE), University Hospital of Wales, Cardiff, UK.
  • Dissemond J; Urticaria Center of Reference and Excellence (UCARE), Department of Immunology, St James's Hospital and Trinity College, Dublin, Ireland.
  • Dogan Günaydin S; Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC (FMABC), Santo André, Brazil.
  • Dorofeeva I; Urticaria Center of Reference and Excellence, (UCARE), Faculdade de Ciências, Médicas e da Saúde de Juiz de Fora (SUPREMA), Hospital Maternidade Therezinha de Jesus, Minas Gerais, Brazil.
  • Ensina LF; Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Ertas R; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Venereology and Allergology, University of Essen, Essen, Germany.
  • Ferrucci SM; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Figueras-Nart I; Urticaria Center of Reference and Excellence (UCARE), Department of Allergy and Immunotherapy, Institute of Immunology, FMBA of Russia, Moscow, Russia.
  • Fomina D; Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
  • Franken SM; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey.
  • Fukunaga A; Urticaria Center of Reference and Excellence (UCARE), Ambulatorio di Dermatologia Allergologica e Professionale, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Giménez-Arnau AM; Urticaria Center of Reference and Excellence (UCARE), The Dermatology Department of the Hospital de Bellvitge, Universitat de Barcelona, Barcelona, Spain.
  • Godse K; Urticaria Center of Reference and Excellence (UCARE), Center of Allergy and Immunology, Moscow Ministry of Healthcare, Moscow, Russia.
  • Gonçalo M; Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Gotua M; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Grattan C; Urticaria Center of Reference and Excellence (UCARE), Division of Dermatology, Kobe University, Graduate School of Medicine, Kobe, Japan.
  • Guillet C; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
  • Inomata N; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, D Y. Patil University School of Medicine, Mumbai, India.
  • Jakob T; Urticaria Center of Reference and Excellence (UCARE), Centro Hospitalar Universitário Coimbra and Faculty of Medicine, University of Coimbra, Clinica de Dermatologia, Coimbra, Portugal.
  • Karakaya G; Urticaria Center of Reference and Excellence (UCARE, Center of Allergy and Immunology, Tbilsi, Georgia.
  • Kasperska-Zajac A; Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Guys & St Thomas' Hospital, London, UK.
  • Katelaris CH; Urticaria Center of Reference and Excellence (UCARE), Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Kosnik M; Urticaria Center of Reference and Excellence (UCARE), Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Allergy ; 76(3): 816-830, 2021 03.
Article in English | MEDLINE | ID: covidwho-960768
ABSTRACT

INTRODUCTION:

The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.

AIM:

To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. MATERIALS AND

METHODS:

Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.

RESULTS:

The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19.

CONCLUSIONS:

The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chronic Urticaria / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Allergy Year: 2021 Document Type: Article Affiliation country: All.14687

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Chronic Urticaria / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Allergy Year: 2021 Document Type: Article Affiliation country: All.14687